


Development of small-molecule drugs for the treatment of leukemia

Prof. Dr. Rainer Riedl, Head of Competence Center for Drug Discovery, rira@zhaw.ch

Acute myeloid leukemia (AML) is driven by leukemia stem cells that resist conventional chemotherapy and are the major cause of relapse. The incidence of AML ranges from three to five cases per 100'000 population. This translates to 40'000 and 20'000 newly diagnosed patients every year in Europe and in the USA, respectively (worldwide 380'000). Only very young and fit patients can undergo intensive curative treatment including allogeneic transplantation. For >80% of all AML patients, treatment is palliative and there is an urgent medical need to develop new treatments. In a project funded by Innosuisse, Michael Brand

and Elias Bommeli from Rainer Riedl's medicinal chemistry research group at the Competence Center for Drug Discovery at the ZHAW Institute of Chemistry and Biotechnology, together with researchers from Inselspital Bern and University Bern (research groups of Carsten Riether and Adrian Ochsenbein), have succeeded in developing a new class of small molecules that selectively target leukemic stem cells. Having patented the results, the research consortium now plans to develop the molecules into a drug for clinical treatment. ■



Pharmacophore model of drug-like small molecules

Neue Projekte

Aroma-beladene mesoporöse Silicapartikel (MSP) für Dropz

Dauer: 01.01.2023 – 01.06.2024

Projektpartner: Forschungsfonds Aargau; dropz AG

Soluble Coffee

Dauer: 01.01.2023 – 01.01.2026

Projektpartner: Haco AG

Therapie für den NRAS-Melanom-Subtyp

Dauer: 01.02.2023 – 30.07.2024

Projektpartner: Innosuisse

Weitere Projekte

zhaw.ch/icbt/projekte

Weiterbildung

01.06.2023

SMGP Grundkurs

07.06.2023

14. Wädenswiler Day of Life Sciences

21.09.2023

SMGP Kurs 3

02.10.2023

CAS in Coffee Excellence

26.10.2023

SMGP Kurs 5

16.11.2023

SMGP Jahrestagung

Infos und Anmeldung

zhaw.ch/icbt/weiterbildung

